Anemia dan Lama Konsumsi Obat Anti Tuberculosis
DOI:
https://doi.org/10.31964/mltj.v3i2.157Keywords:
obat anti tuberculosis, tuberculosis paru, anemiaAbstract
Tuberculosis is an infectious disease due to Mycobacterium tuberculosis germ that can infect several organs, including the lungs, kidneys, and bones. The goal of treatment of tuberculosis is tuberculosis bacilli destroy quickly and prevent recurrence. First category treatment of tuberculosis is isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide. Although the most anti-tuberculosis drug is acceptable in therapy, but have potentially toxic effects hematologic reactions such as agranulocytosis, eosinophilia, thrombocytopenia, and anemia. This research aims to know the correlation between anti-tuberculosis drug consumption in pulmonary TB patients against anemia. Method of this research was Analytical Survey with a Cross-Sectional design. The average results of red blood cell count for 0 months 5,16 106/uL, 2 months 4,39 106/uL and 6 months 4,61 106/uL, haemoglobin levels for 0 month 15,17 g/dL, 2 months 12,73 g/dL and 6 months 13,28 g/dL as well as hematocrit value for 0 month 44,26 %, 2 months 38,24 % and 6 months 39,04 %. From Spearman statistics analytical was obtained significant of red blood cell count 0.004 < α (0.05), levels of hemoglobin 0.007 < α (0.05) and the value of hematocrit 0.015 < α (0.05), it was concluded there was correlation between long consumption of anti-tuberculosis drug with anemia and the value of the correlation coefficient count of red blood cells -0.531, levels of hemoglobin-0.479 as well as the value of hematocrit -0.440 means has the power correlations are medium. Further research is recommended to use different parameters such as the number of platelets, AST/ALT levels and should use the same patient sample or from 0 months up to 6 monthsDownloads
Published
How to Cite
Issue
Section
License
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
